Johnson & Johnson: 3 Key Takeaways for Long-Term Investors

On its third quarter of 2026 earnings call, held on Oct. 13, 2026, Johnson & Johnson (NYSE:JNJ) raised its full-year sales outlook after operational revenue grew 6%. Strong pharmaceutical demand helped the healthcare giant absorb legal costs and medical device headwinds outside the U.S. Three takeaways from the call stand out for long-term investors.

1. Annual Sales Are On Track To Cross a $100 Billion Milestone

The company's Innovative Medicine division, which develops prescription drugs, powered performance with 7.9% operational growth. Cancer treatments led the gains, while Tremfya, an injectable therapy for inflammatory diseases, expanded its market share. This momentum keeps the company on pace to breach a historic sales threshold this year.

With sales in the quarter of more than $25 billion we are on track to meet our guidance and exceed $100 billion in annual revenue for the first time in our company's 140 year history.
-- Joaquin Duato, Chairman and Chief Executive Officer

2. Medical Technology Leadership Is Addressing Temporary Global Growth Headwinds

Operational growth in MedTech, the company's medical device segment, slowed to 2.5% due to disruptions in the Middle East, volume-based procurement, a government bulk-buying program in China, and delays in the adoption of Abiomed heart pumps. Management plans to restore double-digit growth through new product rollouts, including OTTAVA, its soft-tissue robotic surgery system.

Simply put, we can do better, and we absolutely will. And right now, we are focused solely on the actions needed to deliver stronger results in the fourth quarter and beyond.
-- Timothy Schmid, Executive Vice President, Worldwide Chairman, MedTech

3. Portfolio Refinement Favors Spinning Off Orthopedics Over Major Acquisitions

Management clarified that double-digit growth targets rely on internal investments rather than large corporate acquisitions. To streamline operations, the business is leaning toward a tax-free spinoff for DePuy Synthes, its orthopedics subsidiary, by mid-2027.

Given the way DePuy Synthes is performing and the momentum Nimesh Nana and his team are generating, we are leaning toward a spin as being the best option to create long term value for Johnson & Johnson shareholders.
-- Joseph J. Wolk, Executive Vice President and Chief Financial Officer

Looking Ahead

Operational momentum is accelerating into late 2026, and leadership expects further progress next year. High-margin oncology treatments and surgical device rollouts provide durable structural advantages across global markets. Management is watching regulatory timelines for VARIPULSE Pro, an electrophysiology catheter, and commercial preparation for OTTAVA, its soft-tissue robotic surgery platform.

That is why we have the confidence to say that we will finish 2026 strong and that 2027 will be an even better year for Johnson & Johnson.
-- Joaquin Duato, Chairman and Chief Executive Officer

Commercial execution across prescription drugs and medical devices continues to support long-term compounding.

The depth of our portfolio, momentum from new product launches, and upcoming pipeline catalysts further reinforce our conviction in achieving double digit growth by the end of this decade with sustainable growth beyond.
-- Joseph J. Wolk, Executive Vice President and Chief Financial Officer

This article was created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.